Yuanyuan Lv

Jan 16, 2025 | mdpi.com | Jin Liu |Yixin Gao |Yuanyuan Lv |Mengdi Yang

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Jan 16, 2025 | mdpi.com | Jin Liu |Mengdi Yang |Yuanyuan Lv |Yixin Gao

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Dec 20, 2024 | cell.com | Yang Chen |Hao Qin |Nan Li |Yaohua Wei |Yixuan Lin |Ronghui Deng | +10 more

Keywords autologous tumor vaccines tumor membrane antigens neoadjuvant chemotherapy liposomal doxorubicin Introduction Surgery continues to be the primary treatment modality for the majority of solid tumors; however, the challenges of postoperative tumor recurrence and metastasis persist.1,2 Various strategies have been devised in response to these challenges, including using autologous tumor vaccine.3,4,5 These personalized vaccines leverage patients’ tumor cells as a source of antigens to...